Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 7/20 | 0.58 |
| ▸ | MDM4 | O15151 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.57 |
| ▸ | TLR2 | O60603 | 2/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20530570 | 1.00 | MDM2 (0.58) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL4600023 | 0.96 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30278748 | 0.96 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL30854537 | 0.96 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL4600019 | 0.96 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL25362302 | 0.96 | MDM2 (0.57) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL8892538 | 0.93 | MDM2 (0.60) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL8893047 | 0.93 | MDM2 (0.60) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL15681926 | 0.93 | MDM4 (0.59) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL389249 | 0.93 | MDM4 (0.59) | MDM2MDM4TP53TLR2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| CN-110366556-B | Antibacterial peptide macrocyclic compounds and uses thereof | 豪夫迈·罗氏有限公司 | 2024-01-05 | — | — | CN | disclosed |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2022-12-29 | — | — | US | disclosed |
| US-11066443-B2 | Anti-bacterial peptide macrocycles and use thereof | HOFFMANN-LA ROCHE INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3368544-B1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN LA ROCHE (CH) | 2020-06-17 | — | — | EP | disclosed |
| EP-3609904-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| US-20200040031-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | HOFFMANN LA ROCHE (US) | 2020-02-06 | — | — | US | disclosed |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2018-12-20 | — | — | US | disclosed |
| WO-2018189065-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-3388444-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-10-17 | — | — | EP | disclosed |
| EP-3368544-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2018-09-05 | — | — | EP | disclosed |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2017-08-17 | — | — | US | disclosed |
| WO-2017072062-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2017-05-04 | — | — | WO | disclosed |
| US-9493512-B2 | Solution phase processes for the manufacture of macrocyclic depsipeptides and new intermediates | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| EP-2906585-A2 | SOLUTION PHASE PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | Novartis AG (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | NOVARTIS AG (CH) | 2015-08-06 | — | — | US | disclosed |
| WO-2014057418-A2 | SOLUTION PHASE PROCESSES FOR THE MANUFACTURE OF MACROCYCLIC DEPSIPEPTIDES AND NEW INTERMEDIATES | NOVARTIS AG (CH) | 2014-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066443-B2 | Anti-bacterial peptide macrocycles and use thereof | CFTR, VIP, NGLY1 | MDM2 4725/4885MDM4 3930/4885TP53 3587/4885 |
| US-20220411468-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-20200040031-A1 | ANTI-BACTERIAL PEPTIDE MACROCYCLES AND USE THEREOF | CFTR, VIP, NGLY1 | MDM2 4725/4885MDM4 3930/4885TP53 3587/4885 |
| US-20180362578-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-20170233437-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-10030047-B2 | Peptide macrocycles against acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-20150218224-A1 | Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates | VIP, NPPA, DNPEP | MDM2 1393/4885MDM4 1117/4885TP53 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.